Enzalutamide in metastatic prostate cancer before chemotherapy Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Androgen Receptor Antagonists
  • Antineoplastic Agents, Hormonal
  • Phenylthiohydantoin
  • Prostatic Neoplasms

abstract

  • Enzalutamide significantly decreased the risk of radiographic progression and death and delayed the initiation of chemotherapy in men with metastatic prostate cancer. (Funded by Medivation and Astellas Pharma; PREVAIL ClinicalTrials.gov number, NCT01212991.).

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4418931

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1405095

PubMed ID

  • 24881730

Additional Document Info

start page

  • 424

end page

  • 33

volume

  • 371

number

  • 5